Gastroenterology
Volume 132, Issue 3 , Pages 921-930 , March 2007

Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy

  • Wolf Peter Hofmann

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Andreas Polta

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Eva Herrmann

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Ulrike Mihm

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Bernd Kronenberger

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Tanja Sonntag

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Volker Lohmann

      Affiliations

    • Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany
    • ,
  • Barbara Schönberger

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Stefan Zeuzem

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • ,
  • Christoph Sarrazin

      Affiliations

    • Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    • Corresponding Author InformationAddress requests for reprints to: Christoph Sarrazin, MD, Department of Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg/Saar, Germany. fax: (49) 6841-16-21305.

Received 15 June 2006 ,Accepted 16 November 2006.

References 

  1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177:705–706
  2. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16:649–654
  3. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C (A randomized, double-blind, placebo-controlled trial). Ann Intern Med. 1995;123:897–903
  4. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–714
  5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432
  6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  9. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis. 2005;25:72–83
  10. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–924
  11. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–1358
  12. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–972
  13. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A. 2002;99:13374–13376
  14. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6:1375–1379
  15. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol. 2001;75:8074–8081
  16. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol. 2002;76:8505–8517
  17. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol. 2003;77:1092–1104
  18. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310:333–342
  19. Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol. 2005;43:5679–5684
  20. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol. 2005;43:623–629
  21. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology. 2003;38:869–878
  22. Pockros P, Pessoa MG, Diago M, Martinelli ALC, Berg T, Germanidis G, et al. Combination of levovirin (LVV) and PegInterferon alfa-2a (40kD) fails to generate a virological response comparable to ribavirin (RBV) and PegInterferon alfa-2a (40kD) in patients with chronic hepatitis C. Hepatology. 2004;41:525;(abstr)
  23. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol. 2003;77:3007–3019
  24. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–113
  25. Grande-Perez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A. 2002;99:12938–12943
  26. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003;31:3497–3500
  27. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079–11090
  28. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–972
  29. Perelson AS, Ribeiro RM. Mutagenic effects of ribavirin in vivo. J Hepatol. 2005;43:553–555
  30. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002–1009
  31. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63:832–842
  32. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact?. Hepatology. 2003;38:807–810
  33. Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Takahashi M, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol. 2006;44:3562–3568
  34. Mansky LM, Bernard LC. 3′-Azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1. J Virol. 2000;74:9532–9539
  35. Smith RA, Loeb LA, Preston BD. Lethal mutagenesis of HIV. Virus Res. 2005;107:215–228
  36. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol. 2001;75:1437–1449
  37. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol. 2001;75:4614–4624
  38. Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, et al. Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res. 2004;29:89–96
  39. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121–S127
  40. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069

 Supported by the Deutsche Forschungsgemeinschaft (grant KFO129 to E.H., C.S., and S.Z.) and by a young investigator research grant from Saarland University Hospital (1000/T201000076 HOMFOR 06/9 to W.P.H.). For hepatitis C virus replicon system experiments, ribavirin was provided by Schering-Plough Corp (Kenilworth, NJ) and levovirin was provided by Hoffmann-La Roche Ltd, Pharmaceuticals Division (Basel, Switzerland).

PII: S0016-5085(06)02563-7

doi: 10.1053/j.gastro.2006.12.005

Gastroenterology
Volume 132, Issue 3 , Pages 921-930 , March 2007

Article Tools

* Image Usage & Resolution